A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN PEDIATRIC PATIENTS WITH ACTIVE EOSINOPHILIC ESOPHAGITIS
- Registry ID
- R668-EE-1877
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- REGENERON PHARMACEUTICALS INC
- Start date
- 2022-11-04
- Last update
- 2020-06-10
Conditions
Related clinical trials
- A PHASE 4, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL-GROUP, 24 WEEKS, PLACEBO-CONTROLLED STUDY FOLLOWED BY 104 WEEKS OPEN-LABEL TO ASSESS DUPILUMAB EFFICACY ON ESOPHAGEAL FUNCTION AND REMODELING IN ADULT PARTICIPANTS WITH EOSINOPHILIC ESOPHAGITIS (EOE)
- A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED PHASE III EFFICACY AND SAFETY STUDY OF TEZEPELUMAB IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (CROSSING)
- A PHASE 1B/2A, OPEN LABEL TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND
EFFICACY OF EP-104IAR IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS (RESOLVE)
- DOUBLE-BLIND, DOUBLE-DUMMY, RANDOMIZED, PARALLEL-GROUP, NON-INFERIORITY PHASE III TRIAL ON THE EFFICACY AND TOLERABILITY OF 2 MG ONCE DAILY VS. 1 MG TWICE DAILY BUDESONIDE ORODISPERSIBLE TABLETS FOR INDUCTION OF HISTOLOGICAL REMISSION IN ADULTS WITH EOSINOPHILIC ESOPHAGITIS
- A PHASE 3, MULTICENTER, MULTINATIONAL, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
- A PHASE 3, MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED INDUCTION AND MAINTENANCE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-93538 IN ADULT AND ADOLESCENT SUBJECTS WITH EOSINOPHILIC ESOPHAGITIS
View on source registry